XLON
BPCR
Market cap1.10bUSD
Oct 09, Last price
0.97USD
1D
0.00%
1Q
0.63%
IPO
-99.06%
Name
BioPharma Credit PLC
Chart & performance
P/E
8.35
P/S
7.73
EPS
0.12
Div yield, %
9.84%
Shrs. gr., 5y
-3.67%
Rev. gr., 5y
7.88%
Revenues
140m
+12.67%
Net income
130m
+6.31%
CFO
91m
-18.60%
Dividend
Oct 08, 20260.0175 USD/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As an investment trust, BioPharma Credit PLC primarily allocates its portfolio to debt assets that generate interest. The security for these investments is provided by royalty payments or other cash flows stemming from the sales of officially approved life sciences products. The firm was established in 2016 and maintains its headquarters in Exeter, United Kingdom.
Key people
Non-Executive Independent Chairman of the Board · since 2020
Non-Executive Independent Director · since 2016
Senior Non-Executive Independent Director · since 2020
Stephanie Leouzon
Non-Executive Independent Director · since 2018
Sapna Shah
Non-Executive Independent Director · since 2023
Non-Executive Independent Director · since 2020
Headquarters & legal address
19TH FLOOR 51 LIME STREET
LONDON, LND EC3M 7DQ
GB
LONDON, LND EC3M 7DQ
GB
Previous name
PRECIS (2772) PLC
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||